Gradient Investments LLC Has $19.54 Million Holdings in AbbVie Inc. $ABBV

Gradient Investments LLC grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,648 shares of the company’s stock after purchasing an additional 3,721 shares during the quarter. Gradient Investments LLC’s holdings in AbbVie were worth $19,539,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the fourth quarter valued at $28,000. Imprint Wealth LLC raised its position in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie in the 4th quarter worth about $31,000. Legacy Wealth Managment LLC ID lifted its stake in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, WestEnd Advisors LLC lifted its stake in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Up 0.8%

AbbVie stock opened at $245.82 on Friday. The firm has a market capitalization of $434.31 billion, a price-to-earnings ratio of 69.44, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30. The firm’s fifty day moving average price is $241.96 and its two-hundred day moving average price is $224.96. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the firm posted $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research note on Monday. BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Cantor Fitzgerald increased their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Bank of America raised their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.70.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.